Cart
sales@molnova.com
VRX-0466617
CAS No. 926906-64-1
VRX-0466617( VRX 0466617 | VRX0466617 )
Catalog No. M16639 CAS No. 926906-64-1
A potent and selective Chk2 inhibitor with Ki/IC50 of 11 nM/120 nM; shows no inhibitory effect on Chk1 (>100 uM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 963 | Get Quote |
|
| 50MG | 1962 | Get Quote |
|
| 100MG | 2520 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameVRX-0466617
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent and selective Chk2 inhibitor with Ki/IC50 of 11 nM/120 nM; shows no inhibitory effect on Chk1 (>100 uM).
-
DescriptionA potent and selective Chk2 inhibitor with Ki/IC50 of 11 nM/120 nM; shows no inhibitory effect on Chk1 (>100 uM); inhibits the phosphorylation of Chk2 Ser(19) and Ser(33-35), but not of Chk2 Thr(68), prevents the IR-induced Chk2-dependent degradation of Hdmx and attenuates IR-induced apoptosis.
-
In Vitro——
-
In Vivo——
-
SynonymsVRX 0466617 | VRX0466617
-
PathwayAngiogenesis
-
TargetChk
-
RecptorChk
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number926906-64-1
-
Formula Weight462.366
-
Molecular FormulaC19H20BrN5O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN/C(C1=C(NC2=CC=C(NC3=CC=C(Br)C=C3)C=C2)SNC1=O)=N\C(C)CO
-
Chemical Name5-[4-(4-Bromoanilino)anilino]-N'-(1-hydroxypropan-2-yl)-3-oxo-1,2-thiazole-4-carboximidamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Carlessi L, et al. Mol Cancer Ther. 2007 Mar; 6(3):935-44.
2. Carlessi L, et al. Biochim Biophys Acta. 2010 Oct;1803(10):1213-23.
molnova catalog
related products
-
PV-1019
A potent, ATP-competitive and highly selective Chk2 inhibitor with IC50 of 138 nM.
-
CCT-245737
A highly potent, selective, ATP-competitive inhibitor of Chk1 with IC50 of 1.3 nM; weak inhibition on Chk2 (IC50=2440 nM).
-
PHI-101
PHI-101 is an orally available and selective checkpoint kinase 2 (Chk2) inhibitor for the study of refractory acute myelogenous leukemia (AML) and ovarian cancer.
